Support and services
ECMC has dedicated laboratory at Hammersmith Hospital in B-Block that can help with early translational studies.
The type of services that we can offer are:
- Immunohistological analyses
- DNA methylation analyses
- Metabolomic analyses
- Circulating biomarker analyses
What research support is available?
We routinely bank research samples from gynaecological and breast cancer patients and also support sample collection for early phase clinical trials.
Research samples are banked under specific sub-collections registered under Imperial College Healthcare Tissue Bank HTA license or under specific project REC/HRA approval.
We can help collect a range of samples including surgical tissue, biopsy, whole blood, plasma, serum, urine, PBMCs and ascetic/cystic/pleural fluids.
All projects undertaken must be approved by first Cancer Working Group
Contacts at Hammersmith campus
Nona Rama and Cristina Realingo: email@example.com or 07714051439 or x28661/32349
Contacts at Charing Cross campus
Sanela Andrijac, Jessica Lin, Charlotte Ion & Molly Gray: 0203 311 5314 Bleep 5055
ECMC provides biostatistical support (e.g. sample size and power calculation, advice on the study design and statistical analysis plan) for early Phase I/II clinical trials or biomarker evaluation and target identification studies using clinical trial samples. Please note that ECMC remit does not include pre-clinical work in animals or cell lines and biostatistical support is for grant application purpose only. Further statistical support required for the running of the study should be budgeted within the grant application itself.
To request for biostatistical support, please complete the "Application Form to Access Biostatistical Support“ and email the accomplished form to the CRUK Core Resource Manager: Naina Patel at firstname.lastname@example.org.
Applications can be submitted at any time and will be reviewed for approval at the next monthly Cancer Working Group meeting. Approved applications will be scheduled for a consultation with ECMC's statistician, Dr Jingky Lozano-Kuehne. Please note that ECMC’s biostatistical support is not a walk-in or a telephone service and consultations for approved applications can take 1-2 weeks to arrange. A copy of the study protocol as well as relevant references, if available, will be useful during the consultation.
ECMC’s biostatistical support should be acknowledged in study publications. Co-authorship of study publications is appropriate if a statistician has made an intellectual and scientific contribution to the project. If a statistician is a co-author, please ensure that the statistician has approved the manuscript prior to submission for publication.
BRC Circulating Biomarker Facility
The BRC Circulating Biomarker Laboratory is located within the ECMC laboratory and can analyse isolate and analyse single circulating tumour cells (CTCs) and cell-free circulating tumour DNA (ctDNA) from patient samples.
The laboratory is equipped with Cell Search; DEPArray NxT and has access to RainDrop Digital PCR system and Ion Chef/Ion S5 platforms
Contact Dr Grorgios Nteliopoulos email@example.com
We can help with DNA Methylation analysis of specific genes using Bisulfite Pyrosequencing, sample preparation for genome wide methylation profiling using Infinium Array and RQ-RTPCR of key genes. Our laboratory have established assays of over 100 genes.
- Assay design
- Bisulfite conversion
- DNA Methylation analyses
- Global DNA methylation analyses
Nahal Masrour, firstname.lastname@example.org or 020 3313 2349
Our histology laboratory can provide range of histology services for early clinical studies with exploratory endpoints.
- Sectioning of FFPE blocks
- Haematoxylin and Eosin staining (H&E)
- Antibody optimisation
- Immunohistochemistry service
- Tissue microarray construction
Reema Paudel, email@example.com or 020 3313 2349
Currently, the ECMC metabolomics team can support the following analysis:
‒ Biocrates AbsoluteIDQ p180 Kit. Analysis of a panel of ~180 molecules in serum/plasma
- Metabolite classes: amino acids, biogenic amines, acylcarnitines, glycerophospholipids, lyso-glycerophospholipids, sphingolipids and hexoses
- Range of biological pathways and mechanisms for example:
- Phospholipase activity, Activity of carnitine palmitoyltransferase I - CPT-I, Activity of b-oxidation, neurotransmitters, immunosuppression/tolerance, Kynurenine pathway, NO synthases
- The kit provides quantitative results for all the metabolites. It is widely used in epidemiology and drug discovery research and extensively validated. For further nformation see: http://www.biocrates.com/products/research-products/absoluteidq-p180-kit Siskos et al., Anal. Chem., 2017 Jan 3;89(1):656-665.
- A range of in-house HILIC-LC-MS/MS and RP-LC-MS/MS offering targeted profiling assays for a wide range of metabolites in serum/plasma and urine
- Bile acids
- Fatty acids, organic acids
- Amino acids, biogenic amines and related compounds
- TCA cycle intermediates,
- Nucleotides, nucleosides
- Glycolytic pathway intermediates
- Other small molecules (heam metabolites, hippurate, vitamins)
- Xenobiotics and drug metabolites
- Urinary estrogens (Sood et al. BJC 2017, 116;382–388)
- Metabolite labelling with stable isotope tracers
Contact Dr. Alexandros Siskos, firstname.lastname@example.org or Professor Hector Keun, email@example.com
How to access ECMC support?
Who can apply?
Any Imperial College London and Imperial College Healthcare Trust staff involved in early translational cancer research.
Required Criteria for ECMC support.
The project work must meet ECMC remit which is early phase clinical trial/studies or biomarker evaluation and validation
Research support application process
Who can apply? - any cancer researchers at Imperial who are carrying out early phase clinical trials or biomarker evaluation, download the application form.
Download the application form (laboratory support)
Download the application form (biostatistical support)
Any work supported by Imperial ECMC must be acknowledged in study publications.
Suggested acknowledgement text- ‘This work is/was funded by grants from <funder1 and funder2>, and infrastructure support was provided by Imperial Experimental Cancer Medicine Centre, Cancer Research UK Imperial Centre, National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and Imperial College Healthcare NHS Trust Tissue Bank’